(0.00%) 5 206.25 points
(0.06%) 39 020 points
(-0.21%) 18 158 points
(-0.33%) $78.22
(0.82%) $2.21
(-0.33%) $2 323.50
(-0.28%) $27.54
(-0.02%) $964.75
(0.05%) $0.929
(0.36%) $10.86
(0.14%) $0.797
(-0.12%) $91.23
Live Chart Being Loaded With Signals
NightHawk Biosciences, Inc., an integrated biopharmaceutical company, engages in the development of immune therapies and vaccines. The company's therapies are used to modulate the immune system against various diseases, including cancer and infectious diseases...
Stats | |
---|---|
Šios dienos apimtis | 161 222 |
Vidutinė apimtis | 163 739 |
Rinkos kapitalizacija | 10.78M |
EPS | $0 ( 2024-03-29 ) |
Kita pelno data | ( $0 ) 2024-05-13 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -0.202 |
ATR14 | $0.0430 (13.71%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2022-12-07 | Wolf Jeffrey Alan | Buy | 2 843 137 | Stock Option (right to buy) |
2022-12-07 | Smith Edward B Iii | Buy | 101 960 | Stock Option (right to buy) |
2022-12-07 | Prendergast John K A | Buy | 203 921 | Stock Option (right to buy) |
2022-12-07 | Ostrander William L. | Buy | 490 196 | Stock Option (right to buy) |
2022-12-07 | Monahan John J | Buy | 101 960 | Stock Option (right to buy) |
INSIDER POWER |
---|
100.00 |
Last 95 transactions |
Buy: 24 129 486 | Sell: 659 541 |
Tūris Koreliacija
NightHawk Biosciences, Koreliacija
10 Labiausiai teigiamai susiję koreliacijos |
---|
10 Labiausiai neigiamai susiję koreliacijos |
---|
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
NightHawk Biosciences, Koreliacija - Valiuta/Žaliavos
NightHawk Biosciences, Finansinės ataskaitos
Annual | 2022 |
Pajamos: | $5.98M |
Bruto pelnas: | $-420 025 (-7.02 %) |
EPS: | $-1.710 |
FY | 2022 |
Pajamos: | $5.98M |
Bruto pelnas: | $-420 025 (-7.02 %) |
EPS: | $-1.710 |
FY | 2021 |
Pajamos: | $2.11M |
Bruto pelnas: | $0.00 (0.00 %) |
EPS: | $-1.410 |
FY | 2020 |
Pajamos: | $2.95M |
Bruto pelnas: | $0.00 (0.00 %) |
EPS: | $-1.630 |
Financial Reports:
No articles found.
NightHawk Biosciences,
NightHawk Biosciences, Inc., an integrated biopharmaceutical company, engages in the development of immune therapies and vaccines. The company's therapies are used to modulate the immune system against various diseases, including cancer and infectious diseases. Its gp96 platform, including ImPACT, an allogenic cell-based, T-cell-stimulating platform that functions as an immune activator to stimulate and expand T-cells; and ComPACT, which delivers antigen driven T-cell activation and specific co-stimulation in a single product. The company develops HS-110, which has completed enrollment in a Phase II clinical trial to treat patients with advanced non-small cell lung cancer; and HS-130 that is in Phase I clinical trial for the treatment of advanced solid tumors. Its products also include PTX-35, a novel T-cell co-stimulator agonist antibody targeting DR3/TNFRSF25 that is in Phase I clinical trial; DR3/TNFRSF25 for various immunotherapy approaches; and COVID-19 vaccine, which is in preclinical stage. The company has a collaboration with Dr. James Shapiro at University of Alberta to manufacture surrogate mouse version of PTX-35. The company was formerly known as Heat Biologics, Inc. and changed its name to NightHawk Biosciences, Inc. in May 2022. NightHawk Biosciences, Inc. was incorporated in 2008 and is headquartered in Morrisville, North Carolina.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.